About: High titer MVA and influenza A virus production using a hybrid fed-batch/perfusion strategy with an ATF system

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: High titer MVA and influenza A virus production using a hybrid fed-batch/perfusion strategy with an ATF system Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	High titer MVA and influenza A virus production using a hybrid fed-batch/perfusion strategy with an ATF system
Creator	Jordan, Ingo Sandig, Volker Genzel, Yvonne Reichl, Udo Vázquez-Ramírez, Daniel
Source	Medline; PMC
abstract	A cultivation strategy to increase the productivity of Modified Vaccinia Ankara (MVA) virus in high-cell density processes is presented. Based on an approach developed in shake flask cultures, this strategy was established in benchtop bioreactors, comprising the growth of suspension AGE1.CR.pIX cells to high cell densities in a chemically defined medium before infection with the MVA-CR19 virus strain. First, a perfusion regime was established to optimize the cell growth phase. Second, a fed-batch regime was chosen for the initial infection phase to facilitate virus uptake and cell-to-cell spreading. Afterwards, a switch to perfusion enabled the continuous supply of nutrients for the late stages of virus propagation. With maximum infectious titers of 1.0 × 10(10) IU/mL, this hybrid fed-batch/perfusion strategy increased product titers by almost one order of magnitude compared to conventional batch cultivations. Finally, this strategy was also applied to the production of influenza A/PR/8/34 (H1N1) virus considered for manufacturing of inactivated vaccines. Using the same culture system, a total number of 3.8 × 10(10) virions/mL was achieved. Overall, comparable or even higher cell-specific virus yields and volumetric productivities were obtained using the same cultivation systems as for the conventional batch cultivations. In addition, most viral particles were found in the culture supernatant, which can simplify further downstream operations, in particular for MVA viruses. Considering the current availability of well-described perfusion/cell retention technologies, the present strategy may contribute to the development of new approaches for viral vaccine production. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00253-019-09694-2) contains supplementary material, which is available to authorized users.
has issue date	2019-02-23(xsd:dateTime)
bibo:doi	10.1007/s00253-019-09694-2
bibo:pmid	30796494
has license	cc-by
sha1sum (hex)	63fb289aa51f77907321626b838ccae5e0939dc1
schema:url	https://doi.org/10.1007/s00253-019-09694-2
resource representing a document's title	High titer MVA and influenza A virus production using a hybrid fed-batch/perfusion strategy with an ATF system
has PubMed Central identifier	PMC6447503
has PubMed identifier	30796494
schema:publication	Appl Microbiol Biotechnol
resource representing a document's body	covid:63fb289aa51f77907321626b838ccae5e0939dc1#body_text
is schema:about of	named entity 'virus' named entity 'First' named entity 'compared' named entity 'virus' named entity 'magnitude' named entity 'infection' named entity 'availability' named entity 'perfusion' covid:arg/63fb289aa51f77907321626b838ccae5e0939dc1 named entity 'TITER' named entity 'CELL DENSITY' named entity 'NEW' named entity 'AVAILABILITY OF' named entity 'VIRIONS' named entity 'PROPAGATION' named entity 'SYSTEMS' named entity 'SPECIFIC' named entity 'OPTIMIZE' named entity 'GROWTH PHASE' named entity 'RETENTION' named entity 'OPERATIONS' named entity 'CELL SPREADING' named entity 'NUMBER OF' named entity 'VIRAL VACCINE' named entity 'CHEMICALLY DEFINED MEDIUM' named entity 'CELLS' named entity 'SYSTEM' named entity 'USING' named entity 'STRAIN' named entity 'CHOSEN' named entity 'VOLUMETRIC' named entity 'MVA' named entity 'PRESENT' named entity 'CULTURE SUPERNATANT' named entity '2F8' named entity 'REGIME' named entity 'AGE1' named entity 'PIX' named entity 'ANKARA' named entity 'TO INCREASE' named entity 'CELL GROWTH' named entity 'PRODUCTIVITY' named entity 'FOUND' named entity 'PRODUCT' named entity 'ALMOST' named entity 'TOTAL NUMBER' named entity 'SECOND' named entity 'PRODUCTION' named entity 'NUTRIENTS' named entity 'BIOREACTORS' named entity 'ORDER' named entity 'CELL DENSITIES' named entity 'ESTABLISHED' named entity 'VIRUSES' named entity 'CONTINUOUS' named entity 'MANUFACTURING' named entity 'DEVELOPMENT' named entity 'CULTIVATION' named entity 'HIGH' named entity 'INACTIVATED VACCINES' named entity 'CULTURES' named entity 'SYSTEM' named entity 'HYBRID' named entity 'APPROACHES' named entity 'PARTICULAR' named entity 'BASED' named entity 'INFLUENZA A' named entity 'VACCINIA' named entity 'MVA' named entity 'STRATEGY' named entity 'VIRAL PARTICLES' named entity 'BATCH' named entity 'VIRUS PRODUCTION' named entity 'HYBRID' named entity 'ATF' named entity 'STRATEGY' named entity 'CONTRIBUTE '

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software